Business
REGENXBIO Announces Presentations at the 17th Annual WORLDSymposium™ 2021
ROCKVILLE, Md., Feb. 1, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and nine poster presentations will be presented at
About this update from Regenxbio Inc.
[{"type":"text","content":"ROCKVILLE, Md., Feb. 1, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that three oral and nine poster presentations will be presented at the 17th Annual WORLDSymposium™, taking place virtually from February 8 through 12, 2021. The oral presentations include interim results from the Phase I/II clinical trial of RGX-121 for the treatment of mucopolysaccharidosis type II (MPS II).\nThe oral presentations will be presented as follows:\nAbstract Title: Comparative systemic and neurologic effectiveness of intravenous and intrathecal AAV9 delivered individually or combined in a murine model of mucopolysaccharidosis type IPresenter: Lalitha Belur, Ph.D., Assistant Professor Genetics, Cell Bio at University of MinnesotaDate/Time: Monday, February 8, 2021, 10:06 a.m. ET\nAbstract Title: Intracisternal administration of AAV9 gene therapies to target the central nervous systemPresenter: Bryan A. Pukenas, M.D., Assistant Professor of Radiology at Hospital of the University of PennsylvaniaDate/Time: Tuesday, February 9, 2021, 11:36 a.m. ET\nAbstract Title: RGX-121 gene therapy for severe mucopolysaccharidosis type II (MPS II): Interim results of an ongoing first in human trialPresenter: Marie-Laure Nevoret, M.D., Senior Clinical Development Lead at REGENXBIO Date/Time: Thursday, February 11, 2021, 9:42 a.m. ET\nThe poster presentations will be presented as follows:\nAbstract Title: Subretinal injection of RGX-381 to cynomolgus monkeys leads to supraphysiological levels of TPP1 in the eye (poster #24)Presenter: Nicholas Buss, Ph.D., Senior Director, Preclinical Development at REGENXBIO Date/Time: Tuesday, February 9, 2021, from 2:30 to 3:30 p.m. ET\nAbstract Title: Intracisternal administration of AAV9 gene therapies to target the central nervous system (poster #207)Presenter: Bryan A. Pukenas, M.D., Assistant Professor of Radiology at Hospital of the University of PennsylvaniaDate/Time: Tuesday, February 9, 2021, from 2:30 to 3:30 p.m. ET\nAbstract Title: First in-human intracisternal dosing of RGX-111 (adeno-associated virus 9/human α-Liduronidase) for a 20-month-old child with mucopolysaccharidosis type I (MPS I): 1 year follow-up (poster #264)Presenter: Raymond Wang, M.D., Biochemical Genetics Specialist at CHOC Children's HospitalDate/Time: Tuesday, February 9, 2021, from 2:30 to 3:30 p.m. ET\nAbstract Title: RGX-121 ...